Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

Cross-talk between the tumor microenvironment (TME) and cancer cells plays an important
role in acquired drug resistance to epidermal growth factor receptor tyrosine kinase …

Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is a
common feature in human non-small cell lung cancer (NSCLC). STAT3 plays an important …

Tobacco smoking remains the most established cause of lung carcinogenesis and other
disease processes. Over the last 50 years, tobacco refinement and the introduction of filters …

The traditional distinction between small cell lung cancer and non–small cell lung cancer
(NSCLC) is no longer sufficient for treatment planning. It is advised to handle small …

Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …

Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …

β-Galactoside α2, 6-sialyltransferase (ST6Gal-I) has been shown to catalyze α2, 6 sialylation
of N-glycan, an action that is highly correlated with colon cancer progression and …